|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowances of $0 and $10,272, respectively | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Current portion of mortgage note receivable | ||||||||||||||||||||
| Prepaid insurance and services | ||||||||||||||||||||
| Prepaid clinical expenses | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| FURNITURE AND EQUIPMENT, NET | ||||||||||||||||||||
| RIGHT-OF-USE LEASE ASSETS, NET | ||||||||||||||||||||
| MORTGAGE NOTE RECEIVABLE, LESS CURRENT PORTION | ||||||||||||||||||||
| NON-CURRENT PREPAID CLINICAL EXPENSES | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Current portion of lease liabilities | ||||||||||||||||||||
| Current portion of note payable | ||||||||||||||||||||
| Convertible note payable | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| LONG-TERM LIABILITIES | ||||||||||||||||||||
| Long-term note payable, less current portion | ||||||||||||||||||||
| Lease liabilities, net of current portion | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, 0 outstanding | ||||||||||||||||||||
| Common stock, par value $.0001 per share, 250,000,000 shares authorized, 28,768,055 and 28,556,072 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
Loading...
